Tag: cancer research

Oncotarget | MK256 a Novel CDK8 Inhibitor With Potent Antitumor Activity in AML Through Downregulation of STAT Pathway

November 10, 2022

“In summary, our study shows that MK256, a potent and selective CDK8 inhibitor, is an effective negative STAT pathway regulator both in vitro and in vivo in AML.” Listen to… read more

Oncotarget

Oncotarget | Tumor Hyaluronan as Novel Biomarker in Non-Small Cell Lung Cancer: A Retrospective Study

November 9, 2022

“To the best of our knowledge, there have only been 2 other studies (both retrospective) investigating the prognostic potential of HA in NSCLC patients [5, 6].” BUFFALO, NY- November 9,… read more

Oncotarget

Oncotarget | Predictive Molecular Biomarkers for Determining Neoadjuvant Chemosensitivity in Muscle Invasive Bladder Cancer

November 8, 2022

“To our knowledge, our study is the first to use combined differential mRNA and miRNA expression in MIBC to identify a NAC response signature.” BUFFALO, NY- November 8, 2022 –… read more

Oncotarget

Oncotarget | Nectin-4 Widely Expressed in Head and Neck Squamous Cell Carcinoma

November 3, 2022

“In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.” Listen to an audio… read more

Oncotarget

Oncotarget is Again on MEDLINE

October 27, 2022

BUFFALO, NY- October 27, 2022 – On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by MEDLINE/PubMed and PubMed Central/PubMed. Listen to an… read more

Oncotarget

Oncotarget | Therapeutic Efficacy of Humanized JAA-F11 Anti-Thomsen-Friedenreich Antibody Constructs H2aL2a and H3L3 in Human Breast and Lung Cancer Xenograft Models

October 25, 2022

“The potential therapeutic efficacy of the humanized antibodies to TF-Ag-α, hJAA-F11-H2aL2a and hJAA-F11-H3L3, was assessed in human breast and lung cancer xenograft models.” Listen to an audio version of this… read more

Oncotarget

Oncotarget | Platelet-derived Growth Factor (PDGF) Cross-Signaling Via Non-Corresponding Receptors Indicates Bypassed Signaling in Colorectal Cancer

October 20, 2022

“The present study analyzed PDGFR and VEGFR expression in primary colon cancer tissues and CRC cell lines in order to better define their expression profiles. Furthermore, we analyzed putative PDGF… read more

Oncotarget

Oncotarget | Effectiveness of Radiotherapy for Local Control in T3N0 Rectal Cancer Managed With Total Mesorectal Excision: A Meta-analysis

October 13, 2022

“To the best of our knowledge, this is the first study to date to perform a systematic review or meta-analysis regarding the benefit of radiotherapy specific to the T3N0 rectal… read more

Oncotarget

Oncotarget | In vitro Chemotherapy-associated Muscle Toxicity Attenuated With Nutritional Support, While Treatment Efficacy Retained

October 11, 2022

“Our in vitro study demonstrates the importance of specialized nutritional support and combining multiple nutrients to reach maximum effect to attenuate chemotherapy-associated muscle toxicity of skeletal muscle in cancer patients.”… read more

Oncotarget

Oncotarget | Genomic Alterations Predictive of Poor Clinical Outcomes in Pan-cancer

October 4, 2022

PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on September 28, 2022, entitled, “Genomic alterations predictive of poor clinical outcomes in pan-cancer.” Listen to an audio… read more